Genmab — December 2019
-
-
Forty Seven also got a boost, as positive data from its first-in-class candidate against its namesake target- CD47- helped add 80% to the company's market cap. The data add an important proof of concept to the hypothesis of unmasking the so-called 'don't eat me' signal from cancer cells to drive their destruction by macrophages- a fundamental part of the company's foundational technology.
-
But Bernstein's Ronny Gal was pessimistic over the progress of the antibodies in multiple myeloma (MM), noting that the levels of cytokine release syndrome (CRS) management required for both CC-93269 and REGN5458 could mean that the modality "is not categorically safer than CAR-T," potentially limiting its uptake into earlier lines of therapy.
-
Godt med selverkendelse, de småøre er ligegyldige, sæt dig godt ind i dyr rødvin for du skal snart drikke massevis af det. Genmab er ved at udvikle sig til en sværvægter og de store skal passe på ikke at blive overhalet indenom af en dygtig ledet virksomhed med tonsvis af potentiale grundet dygtigt personlige hele vejen rundt. Nogen der husker JDW sagde tonsvis at kandidater, det sværeste var at vælge hvilke til klinikken.
-
For en god ordens skyld. Vi omtaler ikke privatøkonomiske forhold på PI - gerne procenter - ikke antal aktier eller beløb.
-
Er der nogen der kan uddybe lidt omkring Novo's MIM-8 DuoBody præsenteret på ASH? Som jeg læser det er det mere potent end Emicizumab og understøtter videre klinisk udvikling? https://ash.confex.com/ash/2019/webprogram/Paper122817.html
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind